Sanofi Sponsored ADR Stock News

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.

Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker.

Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E, offering a compelling contrarian opportunity despite recent price declines. Strong cash flow, AA credit rating, and a 4.7% yield, plus a robust vaccine and rare disease portfolio, underpin my bullish thesis. Recent M&A, notably the Blueprint acquisition, enhances Sanofi's immunology and rare disease pipeline, supporting fu...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own a...

Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential...

New fund supports nonprofit partners working to address social drivers of health and strengthen community well-being CAMBRIDGE, Mass. , June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community-led solutions to improve health and w...